1. Market Research
  2. > Pharmaceutical Market Trends
PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs

  • March 2015
  • 222 pages
  • ID: 2851879
In this report:
PACIRA'S REVENUE INCREASED ##% YEAR-TO-YEAR, FROM $##.##M IN 2012 TO $##.##M IN 2013 PRIMARILY AS THE RESULT OF GROWTH IN NET SALES OF EXPAREL (BUPIVACAINE), PACIRA'S LEAD PRODUCT.
THE TOTAL DEAL VALUES IN THE BIOTECH SECTOR SOARED TO OVER $## BILLION IN 2013, AN INCREASE OF ##% COMPARED WITH $##.## BILLION IN 2012.

Summary

Table of Contents

Search Inside

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs

Brief

GlobalData's "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" applies our proprietary ranking methodology to compare the challenging positions of 35 mid-cap biotechnology companies on 14 financial metrics. These companies are analyzed based on their financial performance, research and development spending, capital structure, and firm utilization to illustrate the distinct strategies they are using to increase value for their shareholders and create a ambitious advantage. Throughout the market research, GlobalData's Industry Dynamics Team offers expert insight, expanding on each of the metrics discussed.

Additionally to the financial metrics, this market report offers an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, together with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, together with transactions and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value of both marketed and clinical pipeline assets and their future profits and cash flows.

Features

Key Questions Answered

- What particular strategies are these innovative biotech companies employing to gain market share?

- What therapeutic areas are these biotech companies focusing their R&D spending?

- Which forecasts will affect the biotech sector moving forward?

- How does my pipeline and commercialization strategy match up against the competition?

- What particular business development activities are taking place, in terms of partnerships or M&A?

- What unique enabling technologies and drug platforms are these biotech companies developing?

- How are these biotech companies maximizing their capital spend to gain a challenging advantage?

Overview

- This business report offers analysis of the main drivers and forecasts shaping the biotechnology sector; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, business strategy, orphan drugs and asset value creation

- This industry report affords a deep dive into the synergies behind partnering and acquisition activity

- FDA expedited review - drugs approved by Fast Track, Breakthrough, Priority Review, and Accelerated approval pathways

- Six-year forecasts for top drugs approved in 2014; Net Present Value for main drugs approved in 2014.

Great reasons to purchase

- Analyze and track the strategies that these drug companies are using to gain share in the increasingly ambitious market

- Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure

- Organize your sales and marketing strategy to recognize firms with proprietary technologies in order to maximize alternatives for licensing, partnership, equity investment or takeover

- Independent source to benchmark your company's performance against a similar peer group to assess areas of strength/weakness

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026SummaryDry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, ...

2018 Top 10 World’s Leading Pharmaceutical Companies: Capabilities, Goals and Strategies

2018 Top 10 World’s Leading Pharmaceutical Companies: Capabilities, Goals and Strategies

  • $ 6500
  • Industry report
  • August 2018
  • by Venture Planning Group

The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: ...

Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021

Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021

  • $ 6000
  • Industry report
  • July 2018
  • by The Business Research Company

Pharmaceutical Drugs Global Market Opportunities And Strategies By the Drugs For Treatment: Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorde ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on